While stumbles in lung cancer trials have taken Bristol-Myers Squibb share price lower, investors might want to consider this company's stock to be on sale.
Opdivo's advance to the lung cancer front line hits another troubling snag.
Bristol-Myers Squibb's CEO gives reasons to be optimistic about the stock at the J.P. Morgan Healthcare Conference.
Here's how Bristol-Myers Squibb CEO Giovanni Caforio responded to some challenging questions about his company's future.
Bristol-Myers' source of gains in previous years wound up being its primary source of frustration in 2016.
Can Bristol-Myers Squibb grow earnings enough to keep its dividend payments flowing?
What potential dangers lurk for Bristol-Myers Squibb in the new year?
Forty-something investors may want to grab some shares of American Express, Bristol-Myers Squibb, and Starbucks soon.
It's been a rough year for drugmakers, but late clinical-stage failures made it especially tough for these seven companies.
Bristol-Myers Squibb and Gilead Sciences are strong buys after a poor 2016. But Dynavax is probably best avoided after its steep drop-off this year.